You found a trial. It looked perfect — right disease, right location, maybe even testing that drug your oncologist mentioned. You let yourself hope a little. Then you read the eligibility criteria, or worse, you went through screening and got a call saying you don't qualify. Now you're wondering if the whole system is designed to keep patients out.

It's not. But I understand why it feels that way. The eligibility requirements for clinical trials can seem arbitrary, overly strict, or just cruel when you're the one being excluded. Here's what's actually going on — and what you can do when the first door doesn't open.

The uncomfortable truth about why criteria exist

Every trial has inclusion criteria (what you need) and exclusion criteria (what disqualifies you). These lists aren't arbitrary, even when they feel that way.

The first reason is safety — and this one's real, not just legal cover. Clinical trials test treatments that haven't been proven yet. If the experimental drug might destroy your liver and you already have hepatitis, excluding you isn't bureaucratic cruelty. It's keeping you alive. Researchers have seen what happens when the wrong patient gets the wrong experimental treatment. The criteria exist because someone got hurt.

The second reason is scientific: trials need to answer a specific question, and they can only do that if participants are similar enough to compare. If a trial includes people at every disease stage, with every possible treatment history, the results become meaningless noise. Was the drug effective, or did outcomes just reflect who happened to enroll? Strict criteria make the science actually work.

None of this makes rejection feel better. But understanding that the criteria serve a purpose — that they're not just gatekeeping — might help you approach the search differently.

The stuff that gets you in

Inclusion criteria define who the trial wants. The obvious one: you need the diagnosis being studied. But that's rarely enough.

Most trials want specific subtypes. If you have breast cancer, they might need HER2-positive, or triple-negative, or BRCA-mutated. If you have Crohn's, they might want moderate-to-severe with specific inflammation markers. Your general diagnosis gets you in the door; your molecular and clinical details determine if you can stay.

Treatment history matters enormously. Some trials want patients who've already failed standard therapies — "second-line" or "third-line" patients who've run out of conventional options. Others specifically want treatment-naive patients who haven't had any therapy yet. A trial testing a second-line treatment won't take someone who's never had first-line, and vice versa. This trips people up constantly.

Then there's performance status — basically, how functional are you day-to-day? The ECOG scale runs from 0 (totally fine) to 4 (bedridden). Most trials require 0–2, meaning you're up and active more than half the day. This isn't about deserving treatment; it's about whether you can physically handle the trial demands and potential side effects.

The stuff that keeps you out

Exclusion criteria are the dealbreakers. Even if you meet every inclusion criterion, one exclusion can disqualify you.

Other health conditions are the big one. Heart problems, liver disease, kidney issues, uncontrolled diabetes, autoimmune disorders — depending on what's being tested, any of these might exclude you. It's not that you're too sick overall. It's that this specific treatment might interact badly with your specific other condition.

Medications cause problems too. Blood thinners, immunosuppressants, even some supplements can interact with experimental drugs in unknown ways. Sometimes you can stop the medication to qualify; sometimes you can't safely do that. The research team has to evaluate your specific situation.

Washout periods catch people off guard. Many trials require your previous treatment to be completely out of your system — sometimes weeks or months of waiting. If you just finished chemo last week and the trial requires a 28-day washout, you're not rejected forever. You're just not ready yet.

The matching problem (and why it's so hard)

Here's what makes eligibility so frustrating: the criteria are written in medical jargon, buried in dense documents, and checking yourself against them is genuinely difficult. A single trial might have 30+ inclusion and exclusion criteria. Miss one detail on page four and you've wasted weeks pursuing something that was never going to work.

The traditional process involves a research coordinator manually reviewing your records line by line. For complex cases, this takes hours. Things get missed. You get rejected from trials you might have qualified for, or you waste time on trials you never could have joined.

This is the problem AI matching tools like Trialytics are trying to solve — scanning your profile against thousands of criteria simultaneously, catching things humans miss, finding alternatives when one trial doesn't fit. I work for Trialytics, so factor that into how much weight you give this paragraph. But the matching problem is real regardless of how you choose to solve it.

What to do when you don't qualify

First: don't take it personally. A rejection means this particular trial, with this particular treatment and this particular scientific question, isn't the right fit for you right now. It's not a judgment on your worth or your prognosis.

Second: ask questions. Call the research team and ask: Are there other trials at your site I might qualify for? What specifically disqualified me — is it something that might change? Do you know of similar trials with different criteria? Research coordinators talk to each other. They often know about options beyond their own institution.

Third: ask about expanded access. Also called "compassionate use," this is a pathway to get experimental treatments outside of formal trials when you've exhausted other options. The FDA approves thousands of these requests annually. It's not a guarantee, but it's a real option that most patients don't know exists.

Fourth: keep monitoring. New trials open constantly. Your situation might change in ways that make you eligible for studies that didn't fit before. The trial landscape three months from now will look different than it does today.

Questions worth asking

When you're evaluating a trial, don't just read the criteria passively. Ask the coordinators directly:

• Which criteria are hard requirements versus somewhat flexible? The published protocol is often the strictest version. There's sometimes wiggle room that isn't obvious from the documents.
• If I don't meet criterion X, are there similar trials with different requirements? Coordinators often know the competitive landscape.
• How long after my current treatment would I need to wait? If timing is the issue, you can plan around it.
• Is there anything I could do now to become eligible later? Sometimes there's a path forward that isn't obvious.

The bottom line

Eligibility criteria feel like obstacles, and sometimes they function that way. But they're also information. They tell you which trials are designed for people in your exact situation and which ones would waste your time or put you at risk.

Get your medical details organized: diagnosis, biomarkers, treatment history, current medications, recent labs. The more precisely you know your own situation, the more efficiently you can match yourself — or let a matching tool do it for you.

And if one trial says no, that's one trial. It's not the whole universe of options. Keep looking.